JP2016504365A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504365A5
JP2016504365A5 JP2015550767A JP2015550767A JP2016504365A5 JP 2016504365 A5 JP2016504365 A5 JP 2016504365A5 JP 2015550767 A JP2015550767 A JP 2015550767A JP 2015550767 A JP2015550767 A JP 2015550767A JP 2016504365 A5 JP2016504365 A5 JP 2016504365A5
Authority
JP
Japan
Prior art keywords
aryl
compound
heterocyclyl
heteroaryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015550767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/077804 external-priority patent/WO2014105952A2/en
Publication of JP2016504365A publication Critical patent/JP2016504365A/ja
Publication of JP2016504365A5 publication Critical patent/JP2016504365A5/ja
Pending legal-status Critical Current

Links

JP2015550767A 2012-12-28 2013-12-26 Usp1/uaf1デユビキチナーゼ複合体阻害剤及びその使用 Pending JP2016504365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747052P 2012-12-28 2012-12-28
US61/747,052 2012-12-28
PCT/US2013/077804 WO2014105952A2 (en) 2012-12-28 2013-12-26 Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof

Publications (2)

Publication Number Publication Date
JP2016504365A JP2016504365A (ja) 2016-02-12
JP2016504365A5 true JP2016504365A5 (US07794700-20100914-C00125.png) 2016-11-24

Family

ID=49958735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550767A Pending JP2016504365A (ja) 2012-12-28 2013-12-26 Usp1/uaf1デユビキチナーゼ複合体阻害剤及びその使用

Country Status (6)

Country Link
US (1) US9802904B2 (US07794700-20100914-C00125.png)
EP (1) EP2938610A2 (US07794700-20100914-C00125.png)
JP (1) JP2016504365A (US07794700-20100914-C00125.png)
AU (1) AU2013370417A1 (US07794700-20100914-C00125.png)
CA (1) CA2896731A1 (US07794700-20100914-C00125.png)
WO (1) WO2014105952A2 (US07794700-20100914-C00125.png)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013370417A1 (en) 2012-12-28 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
MA41291A (fr) * 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ7阻害物質としてのチエノピリミジノン
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
MX2021001186A (es) 2015-11-20 2022-10-11 Forma Therapeutics Inc Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
CA3014194A1 (en) 2016-02-12 2017-08-17 Forma Therapeutics, Inc. Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
CA3014192A1 (en) * 2016-02-12 2017-08-17 Forma Therapeutics, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
GB201604647D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
KR102327053B1 (ko) * 2017-03-16 2021-11-17 기초과학연구원 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도
KR101986013B1 (ko) * 2017-08-04 2019-06-04 연세대학교 산학협력단 Ml323을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
JP2020530469A (ja) 2017-08-11 2020-10-22 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ阻害剤としてのカルボキサミド
US11413288B2 (en) 2017-11-01 2022-08-16 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
EP3897652A4 (en) 2018-12-20 2022-09-14 KSQ Therapeutics, Inc. SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC TREATMENT PROTEASE 1 INHIBITORS
CN110699453B (zh) * 2019-10-10 2020-09-01 山东大学第二医院 一种胆管癌检测、治疗和预后靶点及应用
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
TW202233621A (zh) 2020-10-30 2022-09-01 美商Ksq治療公司 經取代吡唑并嘧啶之固態形式及其用途
CN114436976B (zh) * 2021-01-29 2023-07-11 石药集团中奇制药技术(石家庄)有限公司 一种新型喹唑啉类衍生物及其制备和应用
WO2022199652A1 (en) * 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
IL307157A (en) * 2021-04-07 2023-11-01 Forma Therapeutics Inc Ubiquitin-specific protease 1 (USP1) inhibition
CN113368112B (zh) * 2021-05-10 2022-09-27 河南农业大学 Usp1-uaf1抑制剂在制备药物中的应用,药物组合物
AU2022386486A1 (en) 2021-11-12 2024-05-09 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CN118660872A (zh) * 2022-04-29 2024-09-17 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
TW202425982A (zh) * 2022-11-04 2024-07-01 大陸商深圳晶泰科技有限公司 泛素特異性蛋白酶1的抑制劑及其應用
WO2024153175A1 (en) * 2023-01-19 2024-07-25 Laekna Therapeutics Shanghai Co., Ltd. Heteroaromatic compounds and their use as usp1 inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1254903B1 (en) 2001-04-20 2005-06-08 Ciba SC Holding AG 4-Amino-2-(pyridin-2-yl)pyrimidine as microbicidal active substances
ES2242839T3 (es) 2001-04-20 2005-11-16 Ciba Specialty Chemicals Holding Inc. 4-amino-2- (piridin-2-il)pirimidina como sustancias activas microbicidas.
WO2003026661A1 (fr) * 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
EP2198867A1 (en) 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
WO2003077656A1 (en) 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
NZ539165A (en) 2002-09-04 2008-03-28 Schering Corp Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
CA2562075C (en) * 2004-04-20 2012-08-14 Transtech Pharma, Inc. Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
CN1984904A (zh) 2004-05-08 2007-06-20 神经能质公司 3-芳基-5,6-二取代哒嗪
KR20060079121A (ko) 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
US20070032499A1 (en) 2005-08-05 2007-02-08 Philippe Guedat Novel cysteine protease inhibitors and their therapeutic applications
WO2008040753A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
JP2010208945A (ja) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
WO2009011910A2 (en) 2007-07-18 2009-01-22 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serices Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
JP2011032169A (ja) * 2007-12-11 2011-02-17 Genecare Research Institute Co Ltd 4−アミノピリミジン誘導体および該化合物を含有する医薬組成物
PH12012500097A1 (en) 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
AR077999A1 (es) * 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
WO2011137320A2 (en) 2010-04-30 2011-11-03 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
EP2566480A4 (en) * 2010-05-07 2014-03-19 California Inst Of Techn METHOD AND COMPOSITIONS FOR INHIBITING THE VALOSIN-CONTAINING PROTEIN
AU2011281015B2 (en) 2010-07-23 2015-09-24 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
AU2011305315A1 (en) 2010-09-24 2013-03-28 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
WO2012061754A2 (en) 2010-11-05 2012-05-10 The Broad Institute, Inc. Compounds and methods for treating autoimmune diseases
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
ES2698847T3 (es) * 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
EP2546684A1 (fr) 2011-07-15 2013-01-16 ETA SA Manufacture Horlogère Suisse Guide de lumière pour l'éclairage d'un dispositif d'affichage d'informations
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
JP2014237590A (ja) * 2011-09-30 2014-12-18 アステラス製薬株式会社 2−(ピリジン−2−イル)ピリミジン−4−アミン化合物又はその塩
EP2780326B1 (en) 2011-10-19 2018-12-26 Vivolux Ab Method for inhibition of deubiquitinating activity
CA2861464C (en) 2012-01-25 2018-03-06 Proteostasis Therapeutics, Inc. Proteasome activity modulating tricyclic compounds
JP2015513317A (ja) 2012-01-25 2015-05-07 プロテオステイシス セラピューティクス,インコーポレイテッド プロテアソーム活性を増強する化合物
AU2013370417A1 (en) 2012-12-28 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof

Similar Documents

Publication Publication Date Title
JP2016504365A5 (US07794700-20100914-C00125.png)
RU2020102453A (ru) Фармацевтические композиции
RU2016130095A (ru) Конъюгат анти-trop2 антитело-лекарственное средство
MX2016004964A (es) Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo.
JP2016503799A5 (US07794700-20100914-C00125.png)
EA201200938A1 (ru) Производные имидазопиридина в качестве ингибиторов jak
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
JP2017531041A5 (US07794700-20100914-C00125.png)
EA201201143A1 (ru) Производные пиразола в качестве ингибиторов jak
JP2014500870A5 (US07794700-20100914-C00125.png)
PE20081888A1 (es) ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3
JP2014508811A5 (US07794700-20100914-C00125.png)
SV2010003463A (es) Compuestos organicos
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
RU2015135722A (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
EA201000614A1 (ru) Производные пурина как лиганды аденозинового рецептора а
MX2012013274A (es) Novedosos derivados de la pirimidina.
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP2017510660A5 (US07794700-20100914-C00125.png)
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы
JP2016537382A5 (US07794700-20100914-C00125.png)
JP2014510147A5 (US07794700-20100914-C00125.png)